Viatris Inc.
VTRSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Viatris Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America,. With a market capitalization of $18.76B, it sits in large-cap territory. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Market Cap
$18.76B
Beta
0.87
P/E (TTM)
—
P/E (Fwd)
6.03
EPS (TTM)
$-0.30
EPS (Fwd)
$2.67
ROE
-2.0%
ROA
2.3%
Cash
$2.40B
Total Debt
$14.61B
Free CF
$2.24B
52W Change
83.3%
Annual Financials
Cash vs Debt
Viatris Inc. carries $14.61B in total debt against $2.40B in cash reserves — debt is roughly 6.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $2.24B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -2.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $17.89B (2021) to $14.30B (2025), a 20% decline worth watching.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Viatris Inc. and its sector.